Haematology Research Review, Issue 13

In this issue:

Escalated weekly alemtuzumab + rituximab in relapsed/refractory CLL
Brentuximab vedotin in relapsed/ refractory HL
High-dose melphalan + autologous SCT in bortezomib-treated MM
Oncogenic CSF3R mutations in CNL/atypical CML
Postchemotherapy RT for paediatric HL in CR
Allogeneic SCT for Fanconi anaemia
IL-6 antagonist as adjunct to replacement haemostasis in haemophilia
Bone marrow reticulin fibrosis in CLL at diagnosis
Pretransplant marrow blasts and allogeneic SCT survival in AML
Impact of bodyweight on FVIII dosing in haemophilia A

Please login below to download this issue (PDF)